Related Experiment Videos
Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts.
André Toulouse1, Faith Au-Yeung, Claudia Gaspar
1Department of Medicine and Research Center, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Suite Y3616-2, 1560 Sherbrooke Street East, Montreal, Quebec H2L 4M1, Canada.
Human Molecular Genetics
|August 10, 2005
Summary
Expanded CAG tract diseases, like spinocerebellar ataxia type 3 (SCA3), involve toxic protein buildup. Frameshifting in these diseases produces harmful polyalanine proteins, suggesting new therapeutic targets.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Expanded CAG tract diseases are late-onset neurodegenerative disorders.
- These disorders are characterized by protein aggregation and neuronal cell death.
- A unifying mechanism for neurodegeneration in these diseases remains elusive.
Purpose of the Study:
- To investigate the occurrence, mechanism, and pathogenic role of ribosomal frameshifting in SCA3.
- To explore the potential therapeutic implications of targeting frameshifting.
Main Methods:
- Establishment of a cellular model to study CAG tract frameshifting.
- Analysis of ribosomal slippage and its dependence on CAG tract length.
- Assessment of the impact of polyalanine-frameshifted proteins on polyglutamine toxicity.
- Evaluation of anisomycin's effect on frameshifting and toxicity.
Main Results:
- Ribosomal frameshifting occurs exclusively to the -1 frame.
- Frameshifting is dependent on the presence of long CAG tracts.
- Polyalanine-frameshifted proteins may exacerbate polyglutamine-associated toxicity.
- Anisomycin reduces -1 frameshifting and associated toxicity.
Conclusions:
- Ribosomal frameshifting contributes to the pathogenesis of expanded CAG tract diseases.
- Targeting frameshifting with drugs like anisomycin presents a potential therapeutic strategy.